Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lynch syndrome-related colorectal carcinomas are NTRK-negative.
Remo A, Grillo F, Vanoli A, Parente P, Mastracci L, Angerilli V, Urso ED, Bergamo F, Fassan M. Remo A, et al. Among authors: bergamo f. Histopathology. 2023 Aug;83(2):335-336. doi: 10.1111/his.14944. Epub 2023 May 17. Histopathology. 2023. PMID: 37195563 No abstract available.
Immunotherapy in Gastrointestinal Cancers.
Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A, Zagonel V, Lonardi S. Procaccio L, et al. Among authors: bergamo f. Biomed Res Int. 2017;2017:4346576. doi: 10.1155/2017/4346576. Epub 2017 Jul 3. Biomed Res Int. 2017. PMID: 28758114 Free PMC article. Review.
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Cremolini C, Milione M, Marmorino F, Morano F, Zucchelli G, Mennitto A, Prisciandaro M, Lonardi S, Pellegrinelli A, Rossini D, Bergamo F, Aprile G, Urbani L, Morelli L, Schirripa M, Cardellino GG, Fassan M, Fontanini G, de Braud F, Mazzaferro V, Falcone A, Pietrantonio F. Cremolini C, et al. Among authors: bergamo f. Br J Cancer. 2018 Apr;118(7):955-965. doi: 10.1038/s41416-018-0015-z. Epub 2018 Mar 13. Br J Cancer. 2018. PMID: 29531324 Free PMC article.
Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?
Loupakis F, Schirripa M, Intini R, Bergamo F, Bertorelle R, Fassan M, Dadduzio V, Merigliano S, Pilati P, Urso ELD, Cillo U, Rugge M, Lonardi S, Zagonel V. Loupakis F, et al. Among authors: bergamo f. Oncologist. 2019 Feb;24(2):e77-e79. doi: 10.1634/theoncologist.2018-0180. Epub 2018 Aug 17. Oncologist. 2019. PMID: 30120156 Free PMC article.
Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization.
Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, Gelsomino F, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, Dei Tos AP, De Maglio G, Martini M, Bergamo F, Zagonel V, Loupakis F, Fassan M. Schirripa M, et al. Among authors: bergamo f. Clin Cancer Res. 2019 Jul 1;25(13):3954-3961. doi: 10.1158/1078-0432.CCR-19-0311. Epub 2019 Apr 9. Clin Cancer Res. 2019. PMID: 30967421
CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer.
Loupakis F, Biason P, Prete AA, Cremolini C, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Intini R, Dadduzio V, Schirripa M, Bergamo F, Antoniotti C, Morano F, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Munari G, Salmaso R, Guzzardo V, Mescoli C, Lonardi S, Rugge M, Zagonel V, Di Maio M, Fassan M. Loupakis F, et al. Among authors: bergamo f. Br J Cancer. 2019 Oct;121(7):593-599. doi: 10.1038/s41416-019-0560-0. Epub 2019 Sep 2. Br J Cancer. 2019. PMID: 31474758 Free PMC article.
Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status.
Loupakis F, Maddalena G, Depetris I, Murgioni S, Bergamo F, Dei Tos AP, Rugge M, Munari G, Nguyen A, Szeto C, Zagonel V, Lonardi S, Fassan M. Loupakis F, et al. Among authors: bergamo f. J Immunother Cancer. 2019 Nov 8;7(1):297. doi: 10.1186/s40425-019-0788-5. J Immunother Cancer. 2019. PMID: 31703605 Free PMC article.
miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer.
Barisciano G, Colangelo T, Rosato V, Muccillo L, Taddei ML, Ippolito L, Chiarugi P, Galgani M, Bruzzaniti S, Matarese G, Fassan M, Agostini M, Bergamo F, Pucciarelli S, Carbone A, Mazzoccoli G, Colantuoni V, Bianchi F, Sabatino L. Barisciano G, et al. Among authors: bergamo f. Br J Cancer. 2020 Apr;122(9):1354-1366. doi: 10.1038/s41416-020-0773-2. Epub 2020 Mar 5. Br J Cancer. 2020. PMID: 32132656 Free PMC article.
Correction: miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer.
Barisciano G, Colangelo T, Rosato V, Muccillo L, Taddei ML, Ippolito L, Chiarugi P, Galgani M, Bruzzaniti S, Matarese G, Fassan M, Agostini M, Bergamo F, Pucciarelli S, Carbone A, Mazzoccoli G, Colantuoni V, Bianchi F, Sabatino L. Barisciano G, et al. Among authors: bergamo f. Br J Cancer. 2020 May;122(10):1576. doi: 10.1038/s41416-020-0855-1. Br J Cancer. 2020. PMID: 32303716 Free PMC article.
223 results